The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Alexandre R. Zlotta

Department of Urology

Erasme Hospital

University Clinics of Brussels

Belgium

[email]@ulb.ac.be

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Department of Urology, Erasme Hospital, University Clinics of Brussels, Belgium. 2000 - 2006

References

  1. Immediate versus deferred androgen-deprivation therapy for prostate cancer: the jury is still out. Zlotta, A.R., Schulman, C. Nature Clinical Practice. Urology (2006) [Pubmed]
  2. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. Zlotta, A.R., Teillac, P., Raynaud, J.P., Schulman, C.C. Eur. Urol. (2005) [Pubmed]
  3. Is seminal vesicle ablation mandatory for all patients undergoing radical prostatectomy? A multivariate analysis on 1283 patients. Zlotta, A.R., Roumeguère, T., Ravery, V., Hoffmann, P., Montorsi, F., Türkeri, L., Dobrovrits, M., Scattoni, V., Ekane, S., Bollens, R., Vanden Bossche, M., Djavan, B., Boccon-Gibod, L., Schulman, C.C. Eur. Urol. (2004) [Pubmed]
  4. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Zlotta, A.R., Giannakopoulos, X., Maehlum, O., Ostrem, T., Schulman, C.C. Eur. Urol. (2003) [Pubmed]
  5. Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long-term data. Zlotta, A.R., Djavan, B. Curr. Opin. Urol (2002) [Pubmed]
  6. Can survival be prolonged for patients with hormone-resistant prostate cancer?. Zlotta, A.R., Schulman, C.C. Lancet (2001) [Pubmed]
  7. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?. Zlotta, A.R., van Vooren, J.P., Huygen, K., Drowart, A., Decock, M., Pirson, M., Jurion, F., Palfliet, K., Denis, O., Simon, J., Schulman, C.C. Eur. Urol. (2000) [Pubmed]
  8. What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer?. Zlotta, A.R., Van Vooren, J.P., Denis, O., Drowart, A., Daffé, M., Lefèvre, P., Schandene, L., De Cock, M., De Bruyn, J., Vandenbussche, P., Jurion, F., Palfliet, K., Simon, J., Schulman, C.C., Content, J., Huygen, K. Int. J. Cancer (2000) [Pubmed]
 
WikiGenes - Universities